nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation
|
Antoine, Alison |
|
|
213 |
C |
p. |
artikel |
2 |
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis
|
D’Ambrosio, Simeone |
|
|
213 |
C |
p. |
artikel |
3 |
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials
|
Sorscher, Steven |
|
|
213 |
C |
p. |
artikel |
4 |
Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial
|
Sun, Lingyun |
|
|
213 |
C |
p. |
artikel |
5 |
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
|
Rossi, Cédric |
|
|
213 |
C |
p. |
artikel |
6 |
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
|
de Groot, Fleur A. |
|
|
213 |
C |
p. |
artikel |
7 |
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
|
Tanaka, Hisashi |
|
|
213 |
C |
p. |
artikel |
8 |
Corrigendum to “Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study” [Eur J Cancer 196 (2024) 113424]
|
Debets, Pien |
|
|
213 |
C |
p. |
artikel |
9 |
Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158]
|
Kron, Anna |
|
|
213 |
C |
p. |
artikel |
10 |
Corrigendum to “Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma” [Eur J Cancer, 207, August 2024, 114173]
|
Hong, Hujian |
|
|
213 |
C |
p. |
artikel |
11 |
Do regulations and policies undermine the social value of independent academic research?
|
Lacombe, Denis |
|
|
213 |
C |
p. |
artikel |
12 |
Editorial Board
|
|
|
|
213 |
C |
p. |
artikel |
13 |
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers
|
Feng, Yingfang |
|
|
213 |
C |
p. |
artikel |
14 |
Epidemiology of men with synchronous metastatic prostate cancer diagnosis – A nationwide 26-year temporal analysis
|
Stroomberg, Hein V. |
|
|
213 |
C |
p. |
artikel |
15 |
Feasibility analysis of using patient-derived tumour organoids for treatment decision guidance in locally advanced head and neck squamous cell carcinoma
|
Fisch, Anne-Sophie |
|
|
213 |
C |
p. |
artikel |
16 |
FIGO 2023 staging for endometrial cancer, when, if it is not now?
|
Matias-Guiu, Xavier |
|
|
213 |
C |
p. |
artikel |
17 |
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
|
Dudnichenko, Oleksandr |
|
|
213 |
C |
p. |
artikel |
18 |
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma
|
Schirizzi, Annalisa |
|
|
213 |
C |
p. |
artikel |
19 |
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
|
Valenza, Carmine |
|
|
213 |
C |
p. |
artikel |
20 |
Immune marker expression and prognosis of early breast cancer expressing HER3
|
Lee, Dae-Won |
|
|
213 |
C |
p. |
artikel |
21 |
Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results
|
Indini, Alice |
|
|
213 |
C |
p. |
artikel |
22 |
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study
|
van Ommen-Nijhof, A. |
|
|
213 |
C |
p. |
artikel |
23 |
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
|
Sini, Claudio |
|
|
213 |
C |
p. |
artikel |
24 |
Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma
|
Zhang, Qixian |
|
|
213 |
C |
p. |
artikel |
25 |
PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort
|
Wang, Yanfei |
|
|
213 |
C |
p. |
artikel |
26 |
Prediabetes persistence or remission and subsequent risk of gallbladder cancer: A nationwide cohort study
|
Park, Joo-Hyun |
|
|
213 |
C |
p. |
artikel |
27 |
Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review
|
AlShammari, Abdullah |
|
|
213 |
C |
p. |
artikel |
28 |
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study
|
Schadendorf, Dirk |
|
|
213 |
C |
p. |
artikel |
29 |
Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival
|
Fujitani, Kazumasa |
|
|
213 |
C |
p. |
artikel |
30 |
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
|
Livraghi, Luca |
|
|
213 |
C |
p. |
artikel |
31 |
Radiomic features of primary retroperitoneal sarcomas: a prognostic study
|
Pasquali, Sandro |
|
|
213 |
C |
p. |
artikel |
32 |
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
|
Tougeron, David |
|
|
213 |
C |
p. |
artikel |
33 |
Response to letter entitled: Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
|
Kron, Anna |
|
|
213 |
C |
p. |
artikel |
34 |
Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: Results of the SHOUT-BC study
|
Ankersmid, J.W. |
|
|
213 |
C |
p. |
artikel |
35 |
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
|
Saalfeld, Felix Carl |
|
|
213 |
C |
p. |
artikel |
36 |
16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated
|
Lu, Lingeng |
|
|
213 |
C |
p. |
artikel |
37 |
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
|
Azad, Arun A. |
|
|
213 |
C |
p. |
artikel |
38 |
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
|
Molinelli, Chiara |
|
|
213 |
C |
p. |
artikel |
39 |
Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial
|
Xiao, Annie |
|
|
213 |
C |
p. |
artikel |
40 |
Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward
|
Locher, Luca |
|
|
213 |
C |
p. |
artikel |